Over The Counter 9 May 2022: The Landscape Of Naloxone Access With HRT’s Michael Hufford
In this episode, HBW Insight speaks to Michael Hufford, co-founder and CEO of Harm Reduction Therapeutics about the inaccessibility in the US of naloxone, a life-saving opioid overdose antidote. Hufford unpacks the history of naloxone access and explains why standing orders aren’t as helpful as they seem. We also explore the incentives for companies currently producing prescription naloxone to make the switch to OTC status, and why many of them have chosen not to. While the financial incentive may not be there, the public health need is dire, and Hufford explains the importance of harm reduction groups and non-profit pharmaceutical companies for getting naloxone into the hands of those who need it the most.
Check out this episode of the Pink Sheet Podcast, where Pink Sheet and HBW Insight reporters and editors discuss comments that FDA commissioner Robert Califf made implying that the FDA might step in to urge manufacturers to pursue an Rx-to-OTC switch of naloxone.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Over The Counter Theme Music:
Copyright 2021 Licensed under a commercial Pixabay License.